Cancer-Focused Medivir Licenses AMR Centre Promising Superbug Assets
Medivir has licensed to the UK's AMR Centre exclusive worldwide rights to its superbug MBLI program in return for a share of eventual sales from generated therapies.
You may also be interested in...
AbbVie takes options on three oncolytic virus immunotherapies under development at Turnstone. Amgen and CytomX swap IP in cancer immunotherapy collaboration, while Nicox and pSivida will team to fight glaucoma and other eye diseases.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.